Sermorelin vs Tesamorelin

Sermorelin: The original GHRH analog and the first FDA-approved peptide secretagogue. Typical dose 200-500 mcg. Tesamorelin: FDA-approved GHRH analog for HIV-associated lipodystrophy with potent GH-releasing activity. Typical dose 1000-2000 mcg. Both fall under the Growth Hormone category.

Stacking Sermorelin with Tesamorelin is a protocol-design question best raised with a clinician — it depends on your goal, current bloodwork, and whether both peptides target overlapping mechanisms. Both peptides should be tracked independently with separate injection sites and timing. PinnyPeptide supports multi-peptide stacks with automatic injection site rotation.

Sermorelin is typically dosed: Once daily before bed (SubQ) for GH optimization / anti-aging; Once daily before bed for Combined with Ipamorelin; Once daily before bed for Pediatric GHD (historical, prescribing-physician only). Tesamorelin is typically dosed: Once daily (SubQ) for HIV lipodystrophy (FDA approved); Once daily for Body composition / anti-aging (off-label).

Sermorelin: Previously FDA approved (1997, as Geref) for pediatric GHD. Brand discontinued 2008. Available in the US via compounding pharmacies on prescription. Tesamorelin: FDA approved. Egrifta (tesamorelin) approved November 2010 for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy. Egrifta SV (reformulated single-vial) approved 2019.